DJSG
VRTX icon

D.J. St. Germain’s Vertex Pharmaceuticals VRTX Stock Holding History

D.J. St. Germain’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.5K Hold
148
– – ﹤0.01% 421
2026
Q1 		$66.1K Sell
148
-13
-8% -$6.06K ﹤0.01% 421
2025
Q4 		$73K Buy
161
+16
+11% +$6.9K ﹤0.01% 437
2025
Q3 		$56.8K Hold
145
– – ﹤0.01% 459
2025
Q2 		$64.6K Hold
145
– – ﹤0.01% 435
2025
Q1 		$70.3K Buy
145
+7
+5% +$3.26K ﹤0.01% 371
2024
Q4 		$55.6K Hold
138
– – ﹤0.01% 407
2024
Q3 		$64.2K Hold
138
– – ﹤0.01% 369
2024
Q2 		$64.7K Hold
138
– – ﹤0.01% 363
2024
Q1 		$57.7K Hold
138
– – ﹤0.01% 377
2023
Q4 		$56.2K Buy
138
+63
+84% +$23.3K ﹤0.01% 378
2023
Q3 		$26.1K Hold
75
– – ﹤0.01% 437
2023
Q2 		$26.4K Buy
+75
New +$25.3K ﹤0.01% 441

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

D.J. St. Germain's VRTX Position: Q2 2026 in Review

D.J. St. Germain held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 148 shares worth $73.5K. The position accounts for ﹤0.01% of the portfolio, ranked #421.

D.J. St. Germain first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. 316 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • D.J. St. Germain held 148 shares of Vertex Pharmaceuticals worth $73.5K as of Q2 2026.
  • D.J. St. Germain left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of D.J. St. Germain's portfolio in Q2 2026, its #421 holding.
  • D.J. St. Germain first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 316 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on D.J. St. Germain's 13F filing for Q2 2026, filed 21 Jul 2026.